Corrigendum to “E1K, a disease-modifying drug candidate for knee osteoarthritis, alleviates pain and regenerates cartilage simultaneously by inhibiting TGF-β1-mediated SMAD1/5/9 signaling in osteoarthritis models” Osteoarthr. Cartil. 34 (2) (2026) 240–250

Key Points

• E1K significantly alleviates pain associated with knee osteoarthritis.
• Inhibition of TGF-β1-mediated SMAD1/5/9 signaling shows promise for cartilage regeneration.
• Observational analysis in osteoarthritis models reveals key mechanisms of E1K.
• The findings suggest potential disease-modifying effects of E1K but require further validation.